Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
Jennifer K Parker,Richard Gu,Gregory A Estrera,Betsy Kirkpatrick,Dusten T Rose,Despoina AI Mavridou,Kristin E Mondy,Bryan W Davies
DOI: https://doi.org/10.2147/IDR.S403448
2023-03-03
Infection and Drug Resistance
Abstract:Jennifer K Parker, 1 Richard Gu, 1 Gregory A Estrera, 1 Betsy Kirkpatrick, 2 Dusten T Rose, 3 Despoina AI Mavridou, 1, 4 Kristin E Mondy, 5 Bryan W Davies 1, 4 1 Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA; 2 Austin Public Health, City of Austin, Austin, TX, USA; 3 Department of Pharmacy, Ascension Seton, Dell Seton Medical Center at The University of Texas, Austin, TX, USA; 4 John Ring LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, TX, USA; 5 Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX, USA Correspondence: Bryan W Davies, Email Purpose: Carbapenem-resistant Enterobacterales (CRE) are subject to intense global monitoring in an attempt to maintain awareness of prevalent and emerging resistance mechanisms and to inform treatment and infection prevention strategies. CRE and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales are not usually examined collectively in regards to their shared pool of resistance determinants. Here, we genetically and phenotypically assess clinical isolates of CRE and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales in the growing region of Central Texas, where CRE are emergent and occurrence of non-carbapenemase-producing-CRE (non-CP-CRE) infections is increasing. Methods: CRE (n=16) and ESBL-producing Enterobacterales (n=116) isolates were acquired from a regional hospital in Central Texas between December 2018 and January 2020. Isolates were assessed genetically and phenotypically using antibiotic susceptibility testing, targeted PCR, and whole genome sequencing. Results: CRE infections are increasing in incidence in Central Texas, and Klebsiella pneumoniae is causing the majority of these infections. Moreover, K. pneumoniae sequence type (ST) 307 is commonly found among both non-CP-CRE and EBSL-producing strains. Isolates carry similar plasmids harboring the gene for the ESBL CTX-M-15 and belong to the global lineage, rather than the Texas lineage, of ST307. Antibiotic resistance profiles, sequence data, and clinical records suggest that porin mutations may promote the transition of ST307 isolates from ESBL-producing to non-CP-CRE. In addition to antibiotic resistance mechanisms, several CRE isolates harbor active colicinogenic plasmids, which might influence the competitiveness of these bacteria during patient colonization. Conclusion: K. pneumoniae of the global ST307 lineage is circulating in Central Texas and is responsible for both non-CP CRE and ESBL-producing Enterobacterales infections. Enhanced surveillance is needed to understand the possible routes for the emergence of non-CP-CRE from EBSL-producing strains. Keywords: beta-lactam, Klebsiella , colicin, genetics, carbapenemase With the prevalence of carbapenem-resistant Enterobacterales (CRE) increasing worldwide, 1,2 long-term management of these challenging resistant strains would benefit from a better understanding of their geographical distribution and spread. It is important to differentiate carbapenemase-producing CRE (CP-CRE) from non-carbapenemase-producing CRE (non-CP-CRE). Acquisition of a single carbapenemase is sufficient for a strain to become CP-CRE, while the resistance mechanism(s) of non-CP-CRE are varied and often difficult to identify. 3,4 Alarmingly, of all CRE isolates cataloged by the Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Laboratory Network (ARLN) in the United States in 2017, 68% were non-CP-CRE. 5 The most common CRE species, in order, are Klebsiella pneumoniae, Enterobacter cloacae species complex, Serratia marcescens, Escherichia coli , and Klebsiella aerogenes . 2 In addition to CRE, another highly prevalent group of beta-lactam-resistant Enterobacterales that causes significant clinical burden, despite remaining susceptible to carbapenems, are the extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. 2,6 Although CRE and ESBL-producing strains often share similar genetic backgrounds, carry some of the same antibiotic-resistance determinants, and endure the same antibiotic pressures from treatment with beta-lactams, they are not always considered collectively when examining the epidemiology of multidrug-resistant Enterobacterales. Further elucidation of the potential relationships between the resistance profiles of CRE and ESBL-producing strains and of the contribution of these relationships to the dissemination of resistance is necessa -Abstract Truncated-
pharmacology & pharmacy,infectious diseases